CorMedix to acquire Melinta Therapeutics for $300M

CorMedix (CRMD) and Melinta Therapeutics announced a definitive agreement for CorMedix to acquire Melinta. The selling shareholders will receive $300 million in total consideration at closing, including $40 million of CorMedix equity, and will be eligible to receive a regulatory milestone of up to $25 million and royalties on net sales of MINOCIN and REZZAYO. The proposed acquisition will expand CorMedix’s team and commercial platform, and increase the commercial portfolio with six marketed, highly differentiated, hospital- and clinic-focused infectious disease products, including REZZAYO, MINOCIN for Injection, VABOMERE, KIMYRSA, ORBACTIV, BAXDELA, and an additional well-established cardiovascular product, TOPROL-XL. REZZAYO is currently approved for the treatment of candidemia and invasive candidiasis in adults, with an ongoing Phase III study for the prophylaxis of invasive fungal infections in adult patients undergoing allogeneic blood and marrow transplantation. The completion of the Phase III study for REZZAYO is expected in 1H 2026. Strategic and Financial Benefits: Strengthens portfolio with multiple growth driving assets – Seven marketed products will add revenue and expanded reach in infectious disease. Diversifies and increases portfolio and revenue base and cash flow – Melinta’s portfolio generated total revenues of $120 million in 2024 and is expected to deliver $125 million to $135 million of revenue for FY 2025. Growth asset in REZZAYO for prophylaxis – Ongoing Phase III study of REZZAYO, if successful, is expected to support a supplemental New Drug Application for expanded use for the prophylaxis of invasive fungal infections in adult patients undergoing allogeneic blood and marrow transplant. If approved, peak annual sales for REZZAYO in this indication could exceed $200 million. Upside growth potential with BARDA collaborations for BAXDELA and VABOMERE – BARDA has awarded Melinta funding for the development of both products for use in pediatric patient populations and against biothreat pathogens. Strong fit with existing CorMedix infrastructure and future deployment needs – With the potential to achieve annual run-rate synergies of $35 million to $45 million in the near-term, the combination sets the stage for the future potential expansion of DefenCath into total parenteral nutrition, for which inpatient utilization is expected to be significant. CorMedix expects that if approved, peak annual sales of DefenCath in the TPN indication will be $150 to $200 million. Acquisition is expected to be highly accretive in 2026 Under the terms of the agreement, which has been approved by the CorMedix and Melinta Board of Directors respectively, CorMedix will pay $300 million in upfront consideration, comprised of $260 million in cash and $40 million in CorMedix equity issued to Melinta shareholders of Deerfield Management Company. The cash consideration will be funded by a combination of CorMedix’s existing cash on hand and the proceeds of a $150 million convertible debt financing with high quality healthcare focused institutional investors, including Deerfield, the terms of which will be described in a Current Report on Form 8-K to be filed by the Company today. The agreement contains an additional regulatory milestone of up to $25 million for the FDA approval of the expanded indication of REZZAYO for prophylaxis of invasive fungal infections in adults undergoing allogeneic blood and marrow transplantation, if this milestone event is achieved by June 30, 2029. Furthermore, the agreement includes tiered royalties on REZZAYO U.S. net sales and low-single-digit royalties on MINOCIN U.S. net sales. The transaction is subject to the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976. The Company expects the transaction to close as early as September 1, 2025.